Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.52 CAD | +3.40% | +4.11% | -15.08% |
Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.08% | 80.99M | |
+2.24% | 42.75B | |
+47.70% | 41.61B | |
+11.98% | 41.34B | |
-8.83% | 26.59B | |
+6.49% | 25.49B | |
-22.92% | 18.12B | |
+30.28% | 12.24B | |
-2.23% | 11.76B | |
+9.19% | 11B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA